299 related articles for article (PubMed ID: 11372672)
1. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome.
Luboshitz J; Lubetsky A; Schliamser L; Kotler A; Tamarin I; Inbal A
Thromb Haemost; 2001 May; 85(5):806-9. PubMed ID: 11372672
[TBL] [Abstract][Full Text] [Related]
2. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
7. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
Eikenboom JC; Tjernberg P; Van Marion V; Heering KJ
Am J Hematol; 2007 Jan; 82(1):55-8. PubMed ID: 16986130
[TBL] [Abstract][Full Text] [Related]
8. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
15. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
16. Acquired von Willebrand's syndrome: a single institution experience.
Kumar S; Pruthi RK; Nichols WL
Am J Hematol; 2003 Apr; 72(4):243-7. PubMed ID: 12666134
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
Borel-Derlon A; Federici AB; Roussel-Robert V; Goudemand J; Lee CA; Scharrer I; Rothschild C; Berntorp E; Henriet C; Tellier Z; Bridey F; Mannucci PM
J Thromb Haemost; 2007 Jun; 5(6):1115-24. PubMed ID: 17403090
[TBL] [Abstract][Full Text] [Related]
18. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
Federici AB
Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
20. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.
Meriane F; Zerhouni L; Djeha N; Goudemand M; Mazurier C
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1023-9. PubMed ID: 8148475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]